[Pepsanurin in congestive heart failure]

Area of Science:

• Cardiology
• Nephrology
• Biochemistry

Background:

• Atrial natriuretic factor (ANF) plays a crucial role in regulating renal function.
• Reduced sensitivity to ANF is observed in patients with congestive heart failure (CHF).
• The underlying mechanisms for ANF resistance in CHF are not fully understood.

Purpose of the Study:

• To investigate the role of a newly identified plasmatic substance, pepsanurin (PU), in modulating ANF's renal effects.
• To determine if plasma levels of PU are elevated in patients with CHF.
• To explore the correlation between PU levels and ANF sensitivity in CHF patients.

Main Methods:

• Pepsanurin (PU) was isolated from plasma samples of healthy controls and CHF patients (Class II-III and Class IV).
• The inhibitory effects of PU on the diuretic and natriuretic actions of ANF were assessed in anesthetized rats.
• Plasma PU levels were indirectly assessed by measuring the degree of ANF inhibition.

Main Results:

• PU significantly inhibited the diuretic and natriuretic effects of ANF in rats.
• The inhibitory effect of PU on ANF was significantly greater in patients with advanced CHF (Class IV) compared to healthy controls (p < 0.02).
• Patients with less advanced CHF (Class II-III) showed inhibition levels comparable to controls.

Conclusions:

• Increased capacity to generate pepsanurin (PU) may contribute to the diminished sensitivity to atrial natriuretic factor (ANF) in patients with advanced congestive heart failure.
• PU represents a potential factor in the pathophysiology of CHF-related fluid and electrolyte imbalances.
• Further research is warranted to elucidate the precise role and therapeutic implications of PU in cardiovascular and renal diseases.